A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
BACKGROUND: In the phase 3 ESSENCE clinical trial, semaglutide demonstrated improved histological outcomes for patients with metabolic dysfunction-associated steatohepatitis (MASH) with moderate or advanced fibrosis. There is limited real-world evide…
Initially developed for type 2 diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now emerging as promising candidates for modifying the course of neurodegenerative diseases. This potential stems from the presence of GLP-1…
Peptide drugs offer considerable potential for treating a diverse range of diseases. Yet, their clinical application is generally restricted to injectable therapies. The main challenge hindering their broader use through globally accessible, patient-…
To compare efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in subjects with type 2 diabetes (T2DM). Electronic databases were searched from inception to 2nd October 2024 for randomised controlled trials comparing GLP-1RAs…
STUDY DESIGN: Retrospective analysis. OBJECTIVE: To evaluate the effects of GLP-1 agonist therapy upon the incidence of pseudarthrosis in patients undergoing multilevel cervical spinal fusion. SUMMARY OF BACKGROUND DATA: The rising prevalence of obes…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) potentially increase the risk of pulmonary aspiration resulting from impaired gastric emptying (IGE). We evaluated the association between GLP-1RAs and IGE using the US Food and Drug Ad…
OBJECTIVE: Randomized clinical trials show that subcutaneous semaglutide is modestly superior to dulaglutide in reducing HbA1c and body weight, but no trial has compared their effectiveness on hard cardiovascular outcomes. This study aimed to examine…
BACKGROUND: Glucagon-like peptide-1 agonists like semaglutide are effective treatments for obesity. High costs may create economic barriers. This study examines the association between income and prescriptions for semaglutide for weight loss. METHODS…
Semaglutide reduces albuminuria and the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease (CKD). We conducted a randomized placebo-controlled double-blind clinical trial in adults with CKD (estimated glome…
Obesity represents a global public health challenge, with specific characteristics and needs in adolescent and elderly populations. GLP-1 (glucagon-like peptide-1) receptor agonists such as liraglutide and semaglutide, as well as the GIP (glucose-dep…
INTRODUCTION: Reports of suicidality associated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been reported to the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). We previously reported an i…
A 69-year-old female with morbid obesity (BMI: 47) and hypertension achieved significant weight loss following treatment with semaglutide. Starting at 241 lb, she lost 90 lb (over 30% of her body weight) over 65 weeks without side effects. This weigh…
Diabetes mellitus is a global disease in which alterations in the internal environment disrupt the bone-fat balance, contributing to osteoporosis. Semaglutide, a single-target, long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), has been…
While obesity and diabetes are prevalent in both men and women, some aspects of these diseases differ by sex. A new blockbuster class of therapeutics, glucagon-like peptide 1 (GLP-1) analogs (eg, semaglutide), shows promise at curbing both diseases.…
IMPORTANCE: Adherence to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is important for their effectiveness. Discontinuation and reinitiation patterns are not well understood. OBJECTIVE: To describe rates of and factors associated with discon…
BACKGROUND AND OBJECTIVE: Obesity is common in heart failure (HF), worsening quality of life and depressive symptoms. While semaglutide, a GLP-1 agonist, aids weight loss in obese adults, its impact on health and mood in obese HF patients is unclear.…
INTRODUCTION: Real-world studies of anti-obesity medication (AOM) use have shown lower adherence and persistence than clinical trials; however, the impact of this reduced adherence in real-world settings remains largely unexplored. This study aimed t…
INTRODUCTION: The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood. METHODS: Patients with IBD treated with GLP1-RA were retrospectively identified f…
Peptides represent a rapidly expanding class of drugs with broad therapeutic potential. However, due to their large molecular weight and susceptibility to degradation in the gastrointestinal tract, most peptide drugs are administered via subcutaneous…